204 related articles for article (PubMed ID: 25560459)
21. Approved LXR agonists exert unspecific effects on pancreatic β-cell function.
Maczewsky J; Kaiser J; Krippeit-Drews P; Drews G
Endocrine; 2020 Jun; 68(3):526-535. PubMed ID: 32146655
[TBL] [Abstract][Full Text] [Related]
22. Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells.
Huang Y; Ning K; Li WW; Lin G; Hou CL; Wang MJ; Zhu YC
Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1082-C1096. PubMed ID: 32938225
[TBL] [Abstract][Full Text] [Related]
23. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
24. Activation of liver-X-receptor α but not liver-X-receptor β protects against myocardial ischemia/reperfusion injury.
He Q; Pu J; Yuan A; Lau WB; Gao E; Koch WJ; Ma XL; He B
Circ Heart Fail; 2014 Nov; 7(6):1032-41. PubMed ID: 25277999
[TBL] [Abstract][Full Text] [Related]
25. Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ.
Zheng F; Zhang S; Lu W; Wu F; Yin X; Yu D; Pan Q; Li H
PLoS One; 2014; 9(6):e101269. PubMed ID: 24972069
[TBL] [Abstract][Full Text] [Related]
26. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
27. LXR agonist regulates the carcinogenesis of PCa via the SOCS3 pathway.
Fu W; Yao J; Huang Y; Li Q; Li W; Chen Z; He F; Zhou Z; Yan J
Cell Physiol Biochem; 2014; 33(1):195-204. PubMed ID: 24481266
[TBL] [Abstract][Full Text] [Related]
28. Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice.
Kim HJ; Yoon KA; Yoon HJ; Hong JM; Lee MJ; Lee IK; Kim SY
J Leukoc Biol; 2013 Jul; 94(1):99-107. PubMed ID: 23657115
[TBL] [Abstract][Full Text] [Related]
29. Activation of liver X receptor inhibits OCT2-mediated organic cation transport in renal proximal tubular cells.
Wongwan T; Kittayaruksakul S; Asavapanumas N; Chatsudthipong V; Soodvilai S
Pflugers Arch; 2017 Nov; 469(11):1471-1481. PubMed ID: 28741179
[TBL] [Abstract][Full Text] [Related]
30. Liver X receptor activation inhibits PC-3 prostate cancer cells via the beta-catenin pathway.
Youlin K; Li Z; Weiyang H; Jian K; Siming L; Xin G
Pathol Res Pract; 2017 Mar; 213(3):267-270. PubMed ID: 28139275
[TBL] [Abstract][Full Text] [Related]
31. Recent progress in liver X receptor-selective modulators.
Ratni H; Wright MB
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):403-13. PubMed ID: 20597026
[TBL] [Abstract][Full Text] [Related]
32. Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.
Archer A; Venteclef N; Mode A; Pedrelli M; Gabbi C; Clément K; Parini P; Gustafsson JÅ; Korach-André M
Mol Endocrinol; 2012 Dec; 26(12):1980-90. PubMed ID: 23073827
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists.
Koura M; Matsuda T; Okuda A; Watanabe Y; Yamaguchi Y; Kurobuchi S; Matsumoto Y; Shibuya K
Bioorg Med Chem Lett; 2015 Jul; 25(13):2668-74. PubMed ID: 25998501
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
[TBL] [Abstract][Full Text] [Related]
35. Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3K/Akt/eNOS signaling pathway activation.
Yu J; Wang Q; Wang H; Lu W; Li W; Qin Z; Huang L
Vascul Pharmacol; 2014 Sep; 62(3):150-61. PubMed ID: 24892989
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of androgen receptor and PSA genes in LNCaP (prostate cancer) cell line due to high concentrations of EGCG, an active ingredient in green tea.
Bakhshandeh N; Mohammadi M; Mohammadi P; Nazari E; Damchi M; Khodabandelu S; Mokhtari H
Horm Mol Biol Clin Investig; 2023 Jun; 44(2):181-186. PubMed ID: 36578191
[TBL] [Abstract][Full Text] [Related]
37. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.
Chuu CP; Chen RY; Kokontis JM; Hiipakka RA; Liao S
Cancer Lett; 2009 Mar; 275(1):86-92. PubMed ID: 18977589
[TBL] [Abstract][Full Text] [Related]
38. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.
Kiss E; Popovic Z; Bedke J; Wang S; Bonrouhi M; Gretz N; Stettner P; Teupser D; Thiery J; Porubsky S; Adams J; Gröne HJ
Am J Pathol; 2011 Jul; 179(1):92-103. PubMed ID: 21703396
[TBL] [Abstract][Full Text] [Related]
39. LXRalpha regulates human CETP expression in vitro and in transgenic mice.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Ubukata N; Terasaka N
Atherosclerosis; 2010 Sep; 212(1):139-45. PubMed ID: 20494359
[TBL] [Abstract][Full Text] [Related]
40. ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells.
Di D; Wang Z; Liu Y; Luo G; Shi Y; Berggren-Söderlund M; Nilsson-Ehle P; Zhang X; Xu N
Biochem Biophys Res Commun; 2012 Apr; 421(1):152-6. PubMed ID: 22516753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
